New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
The Pharma Data
DECEMBER 3, 2020
Food and Drug Administration and European Medicines Agency as we work to bring maribavir to patients.”. Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. About Maribavir. Forward-Looking Statements.
52 
Let's personalize your content